Sandoz Completes Coherus Biosimilar Acquisition

Deal For US Cimerli Ranibizumab Rival To Lucentis Closes ‘Ahead Of Anticipated Timelines’

 
• By David Wallace
  
Eyes US flag
Sandoz now has rights to the ophthalmic biosimilar in the US • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business